Skip to main content
. 2022 Nov 19;2022:9921575. doi: 10.1155/2022/9921575

Table 2.

Exercise habits at month 12 according to sociodemographic and medical variables (Ν = 311).

Variable Inactive (n = 80) Fairly active (n = 92) Active (n = 139)
Age, years M = 53.99 (SD = 7.39) M = 55.79 (SD = 7.91) M = 55.94 (SD = 8.33)
BMI, kg/m2 ≤25 29 (20.6%) 42 (29.8%) 70 (49.6%)
>25 51 (30%) 50 (29.4%) 69 (40.6%)
Country
 Finland 19 (13.3%) 46 (32.2%) 78 (54.5%)
 Portugal 24 (31.6%) 21 (27.6%) 31 (40.8%)
 Israel 20 (37.7%) 15 (28.3%) 18 (34%)
 Italy 17 (43.6%) 10 (25.6%) 12 (30.8%)
Education
 0–9 years 9 (64.3%) 2 (14.3%) 3 (21.4%)
 >9 years 71 (23.7%) 90 (30.4%) 136 (45.9%)
Marital status
 Married/living with a partner 70 (25.7%) 75 (27.6%) 127 (46.7%)
 Single/widowed 10 (25.6%) 17 (43.6%) 12 (30.8%)
Working
 Employed 61 (26.5%) 66 (28.7%) 103 (44.8%)
 Nonemployed/retired 19 (23.5%) 26 (32.1%) 36 (44.4%)
Income
 Very low/low 27 (36.5%) 19 (25.7%) 28 (37.8%)
 Average/high 51 (21.5%) 73 (30.8%) 113 (47.7%)
Tumor grade
 I 9 (17%) 17 (32.1%) 27 (50.9%)
 II 39 (25.7%) 42 (27.6%) 71 (46.7%)
 III 32 (30.2%) 33 (31.1%) 41 (38.7%)
Stage
 I 30 (20.4%) 41 (27.9%) 76 (51.7%)
 II & III 50 (30.5%) 51 (31.1%) 63 (38.4%)
Operation
 Lumpectomy 55 (23.8%) 72 (31.2%) 104 (45%)
 Mastectomy 25 (31.3%) 20 (25%) 35 (43.8%)
Radiotherapy
 Yes 58 (23.5%) 78 (31.6%) 111 (44.9%)
 No 22 (34.4%) 14 (21.9%) 28 (43.8%)
Endocrine treatment
 Yes 63 (24%) 76 (28.9%) 124 (47.1%)
 No 17 (35,4%) 16 (33.3%) 15 (31.3%)
Chemotherapy
 Yes 50 (29.4%) 51 (30%) 69 (40.6%)
 No 30 (21.3%) 41 (29.1%) 70 (49.6%)
Anti-HER2 treatment
 Yes 11 (19.3%) 19 (33.3%) 27 (47.4%)
 No 69 (27.2%) 73 (28.7%) 112 (44.1%)
Psychotropic medication
 Yes 21 (25%) 25 (29.8%) 38 (45.2%)
 No 59 (26%) 67 (29.5%) 101 (44.5%)
Systematic psychological support
 Yes 9 (25%) 14 (38.9%) 13 (36.1%)
 No 71 (25.8%) 78 (28.4%) 126 (45.8%)

BMI = body mass index.